Here are 14 developments in spinal biologics in 2018 so far.
Kleiner Device Labs initiated a full commercial launch of its spinal bone graft delivery tool.
Technavio analysts identified the top three trends of the global spinal biologics market between 2018 and 2022: escalating strategic alliances, increasing number of lumbar fusion cases and increasing adoption of minimally invasive surgery.
Spine Wave launched the GraftMag Graft Delivery System.
In Germany, Thomas Vogl, MD, performed the first cases of Triojection, a system manufactured by Minimus Spine and intended to produce ozone gas for spinal disc herniations.
SpinalCyte completed the first double-blind, placebo-controlled human trial using CybroCell, a human dermal fibroblast injection to treat degenerative disc disease. Patients who received intradiscal injections of SpinalCyte's new cell-based therapy CybroCell showed significantly improved disc height after six months.
Bone Therapeutics finished patient recruitment for its Phase IIA lumbar spinal fusion study with the company's allogeneic bone cell therapy product ALLOB.
Bioventus will co-develop a next-generation bone allograft solution for spine and trauma surgery with Tampa, Fla.-based LifeLink Tissue Bank.
Researchers grafted human spinal cord-derived neural progenitor cells into cervical spinal cord injury sites in rhesus monkeys in a Nature Medicine study. The human stem cells matured into nerve cells in the monkeys, spurring neuronal connections and improving the monkeys' grip.
Gregory Lutz, MD, and Kevin Pauza, MD, launched a new study to examine the clinical effectiveness of Discseel, a treatment to restore and regrow damaged discs in the spine.
Orthobiologics company Cerapedics received FDA approval to initiate a study of P-15L Peptide Enhanced Bone Graft compared to autograft in transforaminal lumbar interbody fusion surgery for degenerative disc disease.
Aziyo Biologics launched OsteGro, an allograft bone matrix designed to support new bone growth in procedures such as hip reconstruction, bone fracture repair and spinal fusion.
DiscGenics presented results from two preclinical studies assessing its IDCT product, a homologous, allogenic, injectable cell therapy.
Regenerative medicine company Mesoblast completed enrollment for its Phase 3 mesenchymal cell therapy trial to treat chronic low back pain due to degenerative disc disease.
RTI Surgical has provided more than 8 million biologic implants that underwent its proprietary sterilization processes with zero confirmed incidents of implant-associated infection.
More articles on biologics:
Mesoblast completes enrollment for chronic low back pain cell therapy trial: 4 things to know
Global orthobiologics market to exceed $5.5B in 2019: 4 highlights